These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 21524831)
1. The first pharmacophore model for potent G protein-coupled receptor 119 agonist. Zhu X; Huang D; Lan X; Tang C; Zhu Y; Han J; Huang W; Qian H Eur J Med Chem; 2011 Jul; 46(7):2901-7. PubMed ID: 21524831 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Sakkiah S; Thangapandian S; John S; Lee KW Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051 [TBL] [Abstract][Full Text] [Related]
3. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification. Islam MA; Pillay TS J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527 [TBL] [Abstract][Full Text] [Related]
4. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening. Jain V; Saravanan P; Arvind A; Mohan CG Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830 [TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling, comprehensive 3D-QSAR, and binding mode analysis of TGR5 agonists. Sindhu T; Srinivasan P J Recept Signal Transduct Res; 2017 Apr; 37(2):109-123. PubMed ID: 27267434 [TBL] [Abstract][Full Text] [Related]
6. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418 [TBL] [Abstract][Full Text] [Related]
7. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors. Ahmadi M; Nowroozi A; Shahlaei M J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810 [TBL] [Abstract][Full Text] [Related]
8. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening. Sindhu T; Srinivasan P Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676 [TBL] [Abstract][Full Text] [Related]
9. Molecular modeling of the 3D structure of 5-HT(1A)R: discovery of novel 5-HT(1A)R agonists via dynamic pharmacophore-based virtual screening. Xu L; Zhou S; Yu K; Gao B; Jiang H; Zhen X; Fu W J Chem Inf Model; 2013 Dec; 53(12):3202-11. PubMed ID: 24245825 [TBL] [Abstract][Full Text] [Related]
10. GPR119 agonists for the treatment of type 2 diabetes. Jones RM; Leonard JN; Buzard DJ; Lehmann J Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700 [TBL] [Abstract][Full Text] [Related]
11. Comparative study on the use of docking and Bayesian categorization to predict ligand binding to nicotinic acetylcholine receptors (nAChRs) subtypes. Kombo DC; Bencherif M J Chem Inf Model; 2013 Dec; 53(12):3212-22. PubMed ID: 24328365 [TBL] [Abstract][Full Text] [Related]
12. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling. Meslamani J; Li J; Sutter J; Stevens A; Bertrand HO; Rognan D J Chem Inf Model; 2012 Apr; 52(4):943-55. PubMed ID: 22480372 [TBL] [Abstract][Full Text] [Related]
13. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders. Shah U Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648 [TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119. Zhang SY; Li J; Xie X Acta Pharmacol Sin; 2014 Apr; 35(4):540-8. PubMed ID: 24681896 [TBL] [Abstract][Full Text] [Related]
15. New strategy for receptor-based pharmacophore query construction: a case study for 5-HT₇ receptor ligands. Kurczab R; Bojarski AJ J Chem Inf Model; 2013 Dec; 53(12):3233-43. PubMed ID: 24245803 [TBL] [Abstract][Full Text] [Related]
16. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. Nieto A; Fernández-Vega V; Spicer TP; Sturchler E; Adhikari P; Kennedy N; Mandat S; Chase P; Scampavia L; Bannister T; Hodder P; McDonald PH Assay Drug Dev Technol; 2018 Jul; 16(5):278-288. PubMed ID: 30019946 [TBL] [Abstract][Full Text] [Related]
17. Discovery of structurally novel, potent and orally efficacious GPR119 agonists. Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443 [TBL] [Abstract][Full Text] [Related]
18. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756 [TBL] [Abstract][Full Text] [Related]
19. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus. Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163 [TBL] [Abstract][Full Text] [Related]
20. A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Tang C; Zhu X; Huang D; Zan X; Yang B; Li Y; Du X; Qian H; Huang W J Mol Model; 2012 Jun; 18(6):2795-804. PubMed ID: 22120948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]